CD274 and cancer: While one would expect that any immunotherapy downregulating PD-L1 would lead to increased immune function and, therefore, decrease viral reactivations, there is clinical evidence of increased rates of HBV reactivation in cancer patients being treated with anti-PD-L1 monoclonal antibodies [135].